Related Experiment Videos

Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from

F Dignan1, D Gujral, M Ethell

  • 1Department of Haemato-oncology, Royal Marsden Hospital, Downs Road, Surrey, UK. fionadignan@hotmail.com

Bone Marrow Transplantation
|May 16, 2007
PubMed

Insights

Defibrotide prophylaxis alone may prevent veno-occlusive disease (VOD) after allogeneic stem cell transplantation (SCT). In a study of 58 patients, no VOD or related deaths occurred, with no bleeding complications observed.

Area of Science:

  • Hematology
  • Transplantation Medicine
  • Pharmacology

Background:

  • Veno-occlusive disease (VOD) is a significant risk following allogeneic stem cell transplantation (SCT).
  • Defibrotide is an established treatment for VOD.

Purpose of the Study:

  • To evaluate the efficacy and safety of defibrotide prophylaxis alone for VOD prevention post-SCT.

Main Methods:

  • Retrospective analysis of 58 patients receiving defibrotide prophylaxis without concurrent heparin.
  • Assessment for VOD using the Baltimore criteria within 100 days post-SCT.
  • Monitoring for hemorrhagic complications.

Main Results:

  • No patients developed VOD according to the Baltimore criteria.
  • No VOD-related deaths occurred within 100 days post-SCT.
  • No hemorrhagic complications were observed in patients receiving defibrotide prophylaxis.

Conclusions:

  • Defibrotide prophylaxis alone may be effective in reducing VOD incidence post-SCT.
  • This prophylactic approach appears safe, with no observed bleeding complications.
  • Further randomized controlled trials are necessary to confirm these findings.

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...